DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Vadadustat
Vadadustat
The Influence of Inflammation on Anemia in CKD Patients
Final Evidence Report
Analytical Approaches in Human Sports Drug Testing
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Clinical Protocol Phase 2, Randomized, Double Blind
Vifor Pharma Announces Akebia's Positive Top-Line Results from Global
Ual Annual Report
JULY 2019 Mrx Pipeline a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Anemia Treatment After 30 Years of Erythropoietic Stimulating Agents: No
Treatments for Anemia in Chronic Kidney Disease: Effectiveness and Value
Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitors Induce Autophagy and Have a Protective Efect in an In-Vitro Ischaemia Model Ayesha Singh1, James W
Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
Snapshot of Anemia in Chronic Kidney Disease
Ferric Citrate
Vadadustat in HD HAASE Et Al
2019 Prohibited List
Anemia of Chronic Diseases: Wider Diagnostics—Better Treatment?
Molecular and Cellular Mechanisms of HIF Prolyl Hydroxylase Inhibitors in Clinical Trials† Cite This: Chem
Top View
Supplementary Information for Molecular and Cellular Mechanisms of HIF Prolyl Hydroxylase Inhibitors in Clinical Trials
Topline Results of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Anemia Due to CKD
Iron Deficiency in Chronic Kidney Disease
Mannose Binding Lectin Is Hydroxylated by Collagen Prolyl-4-Hydroxylase
Anemia in Chronic Kidney Disease: from Pathophysiology and Current Treatments, to Future Agents
2020-USADA-Wallet-Card.Pdf
Recent Advances in Doping Analysis (28)
Preclinical Characterization of Vadadustat
Clinical Protocol Phase 2, Randomized
HIF-Α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: a Comprehensive Review
Annual Report 2020 at a Glance Table of Contents
WALLET CARD2021 Examples of Prohibited and Permitted Substances and Methods Effective Jan
Update on Randomized Clinical Trials in Anemia of CKD KDIGO Chuan-Ming Hao Division of Nephrology, Huashan Hospital Fudan University DISCLOSURES
WHO Drug Information Contents
Iron Therapy in Chronic Kidney Disease: Days of Future Past
Effects of Molidustat in the Treatment of Anemia in Chronic Kidney Disease
Clinical Protocol Protocol No
HIF-PH Inhibitor Vadadustat (MT-6548) Japan Phase 3 Results for the Treatment of Renal Anemia at American Society of Nephrology, Kidney Week 2019